Affordable Access

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.

Authors
  • Candas-Green, Demet
  • Xie, Bowen
  • Huang, Jie
  • Fan, Ming
  • Wang, Aijun
  • Menaa, Cheikh
  • Zhang, Yanhong
  • Zhang, Lu
  • Jing, Di
  • Azghadi, Soheila
  • Zhou, Weibing
  • Liu, Lin
  • Jiang, Nian
  • Li, Tao
  • Gao, Tianyi
  • Sweeney, Colleen
  • Shen, Rulong
  • Lin, Tzu-Yin
  • Pan, Chong-Xian
  • Ozpiskin, Omer M
  • And 12 more
Publication Date
Sep 14, 2020
Source
eScholarship - University of California
Keywords
License
Unknown
External links

Abstract

Although the efficacy of cancer radiotherapy (RT) can be enhanced by targeted immunotherapy, the immunosuppressive factors induced by radiation on tumor cells remain to be identified. Here, we report that CD47-mediated anti-phagocytosis is concurrently upregulated with HER2 in radioresistant breast cancer (BC) cells and RT-treated mouse syngeneic BC. Co-expression of both receptors is more frequently detected in recurrent BC patients with poor prognosis. CD47 is upregulated preferentially in HER2-expressing cells, and blocking CD47 or HER2 reduces both receptors with diminished clonogenicity and augmented phagocytosis. CRISPR-mediated CD47 and HER2 dual knockouts not only inhibit clonogenicity but also enhance macrophage-mediated attack. Dual antibody of both receptors synergizes with RT in control of syngeneic mouse breast tumor. These results provide the evidence that aggressive behavior of radioresistant BC is caused by CD47-mediated anti-phagocytosis conjugated with HER2-prompted proliferation. Dual blockade of CD47 and HER2 is suggested to eliminate resistant cancer cells in BC radiotherapy.

Report this publication

Statistics

Seen <100 times